GYRE
Price
$7.42
Change
+$0.04 (+0.54%)
Updated
Jun 27 closing price
Capitalization
670.2M
50 days until earnings call
ONTTF
Price
$1.89
Change
+$0.04 (+2.16%)
Updated
Jun 27 closing price
Capitalization
1.79B
Interact to see
Advertisement

GYRE vs ONTTF

Header iconGYRE vs ONTTF Comparison
Open Charts GYRE vs ONTTFBanner chart's image
Gyre Therapeutics
Price$7.42
Change+$0.04 (+0.54%)
Volume$1.05M
Capitalization670.2M
Oxford Nanopore Technologies
Price$1.89
Change+$0.04 (+2.16%)
Volume$10.82K
Capitalization1.79B
GYRE vs ONTTF Comparison Chart in %
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONTTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. ONTTF commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Buy and ONTTF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (GYRE: $7.42 vs. ONTTF: $1.89)
Brand notoriety: GYRE and ONTTF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 400% vs. ONTTF: 77%
Market capitalization -- GYRE: $670.2M vs. ONTTF: $1.79B
GYRE [@Biotechnology] is valued at $670.2M. ONTTF’s [@Biotechnology] market capitalization is $1.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileONTTF’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • ONTTF’s FA Score: 1 green, 4 red.
According to our system of comparison, ONTTF is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 3 TA indicator(s) are bullish while ONTTF’s TA Score has 4 bullish TA indicator(s).

  • GYRE’s TA Score: 3 bullish, 6 bearish.
  • ONTTF’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, ONTTF is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а -8.05% price change this week, while ONTTF (@Biotechnology) price change was +12.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ONTTF($1.79B) has a higher market cap than GYRE($670M). ONTTF YTD gains are higher at: 14.894 vs. GYRE (-38.678).
GYREONTTFGYRE / ONTTF
Capitalization670M1.79B37%
EBITDA12.1MN/A-
Gain YTD-38.67814.894-260%
P/E Ratio370.50N/A-
Revenue101MN/A-
Total Cash29.9MN/A-
Total Debt1.59MN/A-
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
99
SMR RATING
1..100
63
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
19

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYREONTTF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
73%
MACD
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
65%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONTTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBBYX28.420.20
+0.71%
First Foundation Total Return Y
GGOSX10.770.06
+0.56%
Goldman Sachs Mid Cap Growth Svc
FMBRX17.850.09
+0.51%
Franklin Mutual Beacon R6
PSVKX16.470.05
+0.30%
PGIM Quant Solutions Small-Cap Val R4
LBSAX34.620.09
+0.26%
Columbia Dividend Income A

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been closely correlated with SPHDF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GYRE jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
+0.54%
SPHDF - GYRE
82%
Closely correlated
N/A
SPRC - GYRE
38%
Loosely correlated
+0.72%
BEAM - GYRE
38%
Loosely correlated
-1.98%
AURA - GYRE
37%
Loosely correlated
-0.16%
OCGN - GYRE
37%
Loosely correlated
-4.46%
More

ONTTF and

Correlation & Price change

A.I.dvisor tells us that ONTTF and LYEL have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ONTTF and LYEL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ONTTF
1D Price
Change %
ONTTF100%
+2.16%
LYEL - ONTTF
26%
Poorly correlated
-1.97%
QSI - ONTTF
26%
Poorly correlated
-3.47%
YECO - ONTTF
22%
Poorly correlated
N/A
GYRE - ONTTF
22%
Poorly correlated
+0.54%
SBMFF - ONTTF
21%
Poorly correlated
N/A
More